DK0915697T3 - Antikonvulsive sulfamatderivater, som er anvendelige ved behandling af fedme - Google Patents

Antikonvulsive sulfamatderivater, som er anvendelige ved behandling af fedme

Info

Publication number
DK0915697T3
DK0915697T3 DK97936939T DK97936939T DK0915697T3 DK 0915697 T3 DK0915697 T3 DK 0915697T3 DK 97936939 T DK97936939 T DK 97936939T DK 97936939 T DK97936939 T DK 97936939T DK 0915697 T3 DK0915697 T3 DK 0915697T3
Authority
DK
Denmark
Prior art keywords
obesity
treatment
derivatives useful
sulfamate derivatives
anticonvulsant sulfamate
Prior art date
Application number
DK97936939T
Other languages
Danish (da)
English (en)
Inventor
Richard P Shank
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21807338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0915697(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of DK0915697T3 publication Critical patent/DK0915697T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Steroid Compounds (AREA)
DK97936939T 1996-06-28 1997-06-23 Antikonvulsive sulfamatderivater, som er anvendelige ved behandling af fedme DK0915697T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2200496P 1996-06-28 1996-06-28
PCT/US1997/010953 WO1998000130A2 (en) 1996-06-28 1997-06-23 Anticonvulsant sulfamate derivatives useful in treating obesity

Publications (1)

Publication Number Publication Date
DK0915697T3 true DK0915697T3 (da) 2003-01-27

Family

ID=21807338

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97936939T DK0915697T3 (da) 1996-06-28 1997-06-23 Antikonvulsive sulfamatderivater, som er anvendelige ved behandling af fedme

Country Status (24)

Country Link
US (1) US6071537A (de)
EP (1) EP0915697B1 (de)
JP (1) JP2000514425A (de)
CN (1) CN1106193C (de)
AP (1) AP1285A (de)
AT (1) ATE224189T1 (de)
AU (1) AU732923B2 (de)
BR (1) BR9710994A (de)
CA (1) CA2258893C (de)
CZ (1) CZ293876B6 (de)
DE (1) DE69715631T2 (de)
DK (1) DK0915697T3 (de)
ES (1) ES2184127T3 (de)
HK (1) HK1018743A1 (de)
HU (1) HU226775B1 (de)
IL (1) IL127715A (de)
NO (1) NO317754B1 (de)
NZ (1) NZ333586A (de)
PT (1) PT915697E (de)
RU (1) RU2214241C2 (de)
SK (1) SK284305B6 (de)
UA (1) UA53655C2 (de)
WO (1) WO1998000130A2 (de)
ZA (1) ZA975772B (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
ATE294577T1 (de) * 1999-02-24 2005-05-15 Univ Cincinnati Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
US6201010B1 (en) * 1999-04-08 2001-03-13 Ortho-Mcneil Pharmceutical, Inc. Anticonvulsant derivatives useful in lowering blood pressure
NZ514811A (en) * 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
CA2369093C (en) * 1999-04-08 2005-10-18 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in lowering lipids
JP4709392B2 (ja) * 1999-04-08 2011-06-22 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 血液グルコースレベルを下げることに有用な抗痙攣薬誘導体
WO2000061140A1 (en) * 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7056890B2 (en) * 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7659256B2 (en) * 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
BR0112519A (pt) 2000-07-07 2004-03-30 Ortho Mcneil Pharm Inc Derivados anticonvulsivantes úteis para prevenir o desenvolvimento de diabetes melito do tipo ii e sìndrome x
DE10035227A1 (de) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
US6946243B2 (en) 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
PT1333887E (pt) * 2000-10-30 2006-10-31 Ortho Mcneil Pharm Inc Metodo de tratamento de desordens musculares
EP1345602B1 (de) * 2000-11-30 2010-07-21 Novodermix International Limited Heilung von wunden
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20050025791A1 (en) * 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
JP4906233B2 (ja) * 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ 少なくとも１種の有効薬剤成分を含有する多構成要素固相
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
CA2483464C (en) * 2002-05-17 2011-12-20 Duke University Method for treating obesity
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7208477B2 (en) * 2002-12-02 2007-04-24 University Of Florida Research Foundation, Inc. Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
ES2303085T3 (es) 2003-04-29 2008-08-01 Orexigen Therapeutics, Inc. Composiciones que afectan a la perdida de peso.
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
JP2007517901A (ja) 2004-01-13 2007-07-05 デューク・ユニバーシティー 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
WO2005107806A1 (en) * 2004-04-21 2005-11-17 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
JP2007536229A (ja) * 2004-05-03 2007-12-13 デューク・ユニバーシティー 体重減少に作用するための組成物
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
KR20070057848A (ko) * 2004-08-24 2007-06-07 얀센 파마슈티카 엔.브이. 항경련제로 유용한 신규 벤조-융합된 헤테로아릴 설파미드유도체
AU2006249577A1 (en) * 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
BRPI0618918B8 (pt) 2005-11-22 2021-05-25 Nalpropion Pharmaceuticals Llc uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191459A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191453A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
EP2026790A2 (de) * 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Kombinationstherapie zur behandlung von epilepsie und assoziierten erkrankungen
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20190042766A (ko) 2006-11-09 2019-04-24 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
MX343867B (es) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
BRPI0915890A2 (pt) 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
EP2858640B1 (de) 2012-06-06 2020-03-25 Nalpropion Pharmaceuticals LLC Zusammensetzung zur Verwendung in einem Verfahren zur Behandlung von Übergewicht und Fettleibigkeit in Patienten mit hohem Herz-Kreislauf-Risiko
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US10278948B1 (en) 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4586916A (en) * 1985-01-30 1986-05-06 Consolidated Papers, Inc. Corrugated carton separator
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates

Also Published As

Publication number Publication date
AP9801429A0 (en) 1998-12-31
RU2214241C2 (ru) 2003-10-20
NO986052L (no) 1999-02-23
BR9710994A (pt) 2000-10-24
HK1018743A1 (en) 2000-01-07
ATE224189T1 (de) 2002-10-15
IL127715A (en) 2004-07-25
WO1998000130A3 (en) 1998-02-12
ZA975772B (en) 1998-12-28
JP2000514425A (ja) 2000-10-31
NO986052D0 (no) 1998-12-22
US6071537A (en) 2000-06-06
WO1998000130A2 (en) 1998-01-08
HUP0001192A3 (en) 2002-09-30
AU732923B2 (en) 2001-05-03
AP1285A (en) 2004-06-24
CZ293876B6 (cs) 2004-08-18
CA2258893A1 (en) 1998-01-08
NZ333586A (en) 2000-05-26
CA2258893C (en) 2005-06-14
SK180598A3 (en) 2000-07-11
PT915697E (pt) 2003-02-28
ES2184127T3 (es) 2003-04-01
SK284305B6 (sk) 2005-01-03
AU3957897A (en) 1998-01-21
NO317754B1 (no) 2004-12-13
CZ427898A3 (cs) 1999-08-11
DE69715631T2 (de) 2003-05-08
EP0915697A2 (de) 1999-05-19
IL127715A0 (en) 1999-10-28
CN1106193C (zh) 2003-04-23
HUP0001192A2 (hu) 2000-11-28
CN1224352A (zh) 1999-07-28
DE69715631D1 (de) 2002-10-24
HU226775B1 (en) 2009-09-28
EP0915697B1 (de) 2002-09-18
UA53655C2 (uk) 2003-02-17

Similar Documents

Publication Publication Date Title
DK0915697T3 (da) Antikonvulsive sulfamatderivater, som er anvendelige ved behandling af fedme
DE69810179T2 (de) Titannitridfilme
DE69901014D1 (de) Keilantriebsvorrichtung
DE59705833D1 (de) Biaxialmischer
DK0808307T3 (da) Bicykliske isothiourinstofderivater, som kan anvendes ved terapi
FI974099A0 (fi) Dricksburkslock som kan oeppnas med en hand
DK0932400T3 (da) Antikonvulsive derivater, der er nyttige ved behandling af neuropatisk smerte
BR9709096A (pt) Processo para a preparação de 4,6-di-hidróxi-pirimidina
FI941307A0 (fi) Tjulvalarm, som aktiveras av foeremaolets, som skall skyddas, roerelse
ID15994A (id) Penuntun rantai sambungan
FI961985A0 (fi) Oscillatorkrets
FI961984A0 (fi) Oscillatorkrets
DK0927580T3 (da) Håndbruser
FI961986A0 (fi) Oscillatorkrets
ES1038653Y (es) Bisagra desmontable perfeccionada.
ES1039166Y (es) Revestimiento para bañeras usadas deterioradas.
ES1028213Y (es) Ducha perfeccionada.
ES1031096Y (es) Ducha antivandalica.
ATA128198A (de) Dusche
DE29708153U1 (de) Humerus-Fraktur-Orthese
KR970050970U (ko) 아이샤워
DE29718530U1 (de) Duscheinheit
ES1037887Y (es) Cajon perfeccionado.
FI960434A0 (fi) Slaganordning som arbetar med hydrauliskt tryck
ES1028714Y (es) Dispositivo para la sujecion de bañeras.